期刊文献+

过氧化物酶体增殖物激活受体γC161→T基因多态性与代谢综合征的相关研究

Relationship of Peroxisome Proliferator Activated Receptor Gamma C161T Gene Polymorphism with Metabolic Syndrome
暂未订购
导出
摘要 目的探讨过氧化物酶体增殖物激活受体γ(PPARγ)基因C161→T多态性在宁夏人群中的分布及其与代谢综合征(MS)的关系。方法运用横断面的调查的方法,选取175例健康对照者,平均年龄(47.30±11.6)岁和175例代谢综合征患者,平均年龄(48.73±12.50)岁,采用聚合酶链反应和限制性片段长度多态性方法(PCR-RFLP)检测人群中的PPARγ基因C161→T位点多态性,并对不同基因型患者代谢综合征的危险性进行评价。结果⑴代谢综合征组、对照组T等位基因频率分别为0.253、0.240,C等位基因频率分别为0.747、0.760;C、T等位基因频率在各组间分布差异无统计学意义;⑵PPARγC161CC基因型的总胆固醇(TC)水平高于TT型。结论 PPARγC161→T基因多态性与代谢综合征有关,即代谢综合征患者CC基因型总胆固醇水平相对较高。 Objective To investigate the association of PPARγC161→T gene polymorphism with metabolic syndrome in Chinese people of Ninxia.Methods Cross-sectional survey method was used for investigation.,The polymorphism of PPARγC161→T gene of 175 metabolic syndrome patients were determined by PCR-PFLP method to detect.The risk of metabolic syndrome with different genotypes was evaluated.Results ⑴ In the groups of metabolic syndrome and nomal health,'T'allele frequency was 0.253,0.240 respectively;and 'C'allele frequency was 0.747,0.760 respectively.There was no significant difference between the groups.⑵The total cholesterol in CC genotypes in patients with metabolic syndrome was significantly higher than that in TT.Conclusion PPARγC161 →T gene polymorphism can influence the level of lipoprotain metabolism and FBS.CC allele is associated with higher level of total cholesterol it may influence the process of metabolic syndrome.
出处 《宁夏医科大学学报》 2012年第3期204-207,221,共5页 Journal of Ningxia Medical University
基金 国家自然科学基金资助项目(81060235) 宁夏卫生厅科技项目
关键词 氧化物酶体增殖物激活受体γ 基因多态性 代谢综合征 peroxisome proliferator activated receptor gamma gene polymorphism metabolic syndrome
  • 相关文献

参考文献5

二级参考文献50

  • 1Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPABs): Novel therapeutic targets in renal disease. Kidney Int, 2001, 60 : 14 -30.
  • 2Bishop-Bailey D, ttla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor ligand 15-deoxy-delta12,14 prostaglandin J2. J Biol Chem, 1999,274 : 17042 - 17048.
  • 3Oliver WR, Shenk JL, Snaith MR, et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA,2001, 98 : 5306 -5311.
  • 4Oberfield JL, Collins JL, Holmes CP, et al. A peroxisome proliferator- activated receptor gamma ligand inhibits adipocyte differentiation. Proc Nail Acad Sci USA, 1999, 96 :6102 -6126.
  • 5Schoanjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor in mediating effects of fibrates and fatty acids on gene expression. J Lipid Res, 1996, 37 :907 -925.
  • 6Stacls B, Koenig W, Habib A, et al. Activation of human aortic smooth muscle cells is inhibited by PPARα but not by PPART activators. Nature, 1998, 393 : 790-793.
  • 7Guan Y, Zhang YH, Schneider A, et al. Peroxisome proliferator-activated receptor-T activity is associated with renal microvasculature. Am J Physiol Renal Physiol, 2001,281 :1036 - 1046.
  • 8Ye JM, Iglesias MA, David GW, et al. PPARα/γ ragaglitazar eliminates fatty liver and enhances insulin action in fatfed rats in the absence of hepatomegaly. Am J Physiol Endocrinol Metab, 2003, 284 : 531 -540.
  • 9Guan Y, Breyer MD. Targeting peroxisome proliferator-activated receptors (PPARs) in kidney and urologic disease.Minerva Urol Nefrol, 2002,54: 65 ~79.
  • 10Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int, 2001,60: 14~30.

共引文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部